Klein A, Sami M, Selinger K
Clin Pharmacol Ther. 1985 Jun;37(6):669-73. doi: 10.1038/clpt.1985.109.
Cimetidine, a commonly used H2-receptor antagonist, was found to interact adversely with many drugs, including class I antiarrhythmics such as lidocaine and quinidine. To test the effect of cimetidine on the kinetics of mexiletine, a class I antiarrhythmic similar to lidocaine, the absorption and disposition of mexiletine were followed in six healthy subjects before and after 1 week of cimetidine, 300 mg by mouth four times a day. Cimetidine did not alter the distribution and elimination of mexiletine, as shown by similar mean kinetics including total body clearance, AUC, and the elimination t1/2 before and after cimetidine treatment. Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml). We conclude that cimetidine does not alter the disposition of oral mexiletine in normal subjects.
西咪替丁是一种常用的H2受体拮抗剂,已发现它会与许多药物发生不良相互作用,包括I类抗心律失常药,如利多卡因和奎尼丁。为了测试西咪替丁对美西律(一种与利多卡因类似的I类抗心律失常药)动力学的影响,在6名健康受试者中,跟踪了口服西咪替丁(每日4次,每次300mg)1周前后美西律的吸收和处置情况。西咪替丁并未改变美西律的分布和消除,西咪替丁治疗前后的总体清除率、AUC和消除t1/2等平均动力学参数相似即表明了这一点。西咪替丁对美西律的吸收确实有显著影响,表现为平均吸收t1/2延长(从0.20±0.14小时延长至0.61±0.35小时)、美西律浓度达峰的平均时间延长(从1.13±0.31小时延长至1.88±0.83小时)以及美西律血浆浓度降低(从0.74±0.19mg/ml降至0.59±0.15mg/ml)。我们得出结论,西咪替丁不会改变正常受试者口服美西律的处置情况。